KPMG Partners with Hippocratic AI to Address Healthcare Workforce Shortages

Tax, audit and advisory firm KPMG has announced a collaboration with generative AI company Hippocratic AI to address global healthcare workforce shortages through the deployment of AI agents. The partnership leverages Hippocratic AI's Polaris Constellation architecture, which includes generative AI healthcare agents designed to assist with various healthcare workflows ranging from patient intake to care management follow-up calls.

KPMG is conducting comprehensive process analyses to identify high-pressure points within healthcare systems and upskill workforces. The firm aims to strategically expand the workforce with AI and "strategically plan for the highest-impact deployment of AI across the entire care continuum." The initiative focuses on using conversational agents that can interact with humans naturally and intuitively, comprehending, processing, and responding to human conversation in contextually relevant and human-like behavior.

The primary objective is to free up provider time, allowing healthcare professionals to focus more on direct patient care while AI agents handle time-consuming administrative and follow-up tasks. This approach addresses the critical shortage of healthcare workers globally while maintaining the quality of patient interactions and care delivery.

"Hippocratic AI's collaboration with KPMG is deeply aligned in purpose and vision," said Munjal Shah, founder and CEO of Hippocratic AI. "Their holistic approach to digital and clinical transformation focuses on improving patient outcomes and optimizing healthcare efficiency. We appreciate their commitment to driving meaningful impact across the entire care journey with generative AI, while preserving the human touch of clinicians and the integrity of healthcare operations."

Hippocratic AI has been rapidly expanding its presence in the healthcare sector. Recent deployments include partnerships with Universal Health Services at facilities in Las Vegas and Texas for post-discharge patient follow-up, and collaborations with Eucalia for the Japanese market and Burjeel Holdings in the Middle East. The company's momentum is backed by substantial funding, having closed a $141 million Series B round in January 2025 that valued the company at $1.64 billion. These funds are being used to expand into new markets including pharmaceutical and payer sectors, as well as new geographic regions across EMEA, Latin America, and Southeast Asia.

Click here for the original news story.